The cushing's disease market addresses a rare endocrine disorder characterized by the overproduction of cortisol. Patients typically exhibit a range of symptoms, including weight gain, high blood pressure, and mood disturbances. The primary cause is often a benign pituitary tumor. Treatment options vary, with surgery to remove the tumor being the most common approach. In cases where surgery is not feasible or successful, other therapies, such as medications to control cortisol levels, may be employed. Ongoing research and advancements aim to improve treatment outcomes for those affected by cushing's disease.
According to Data Bridge Market Research, the Global Cushing's Disease Market was valued at USD 333.80 million in 2021 and is expected to reach USD 686.89 million by 2029, registering a CAGR of 9.44% during the forecast period of 2022 to 2029.
“Increasing investment in healthcare infrastructure boosts the market’s growth”
The driver behind the growth of the cushing's disease market is the increasing investment in healthcare infrastructure. As healthcare systems expand and become more sophisticated, there is an improved capacity for early detection, diagnosis, and treatment of rare disorders such as cushing's disease. Advanced medical facilities and specialized centers for endocrine disorders offer patients better access to the latest diagnostic tools and treatment options. This investment in healthcare infrastructure contributes to better patient outcomes and fuels market growth.
What restraints the growth of the global cushing's disease market?
“High cost restraints the market’s growth”
A significant restraint in the cushing's disease market is the high cost associated with its diagnosis and treatment. The diagnostic procedures, including advanced imaging and hormonal tests, can be expensive. Additionally, treatment options, such as surgery or long-term medication, are also financially demanding. This high cost can create barriers to access and limit care affordability, potentially hindering patient treatment and affecting the market's growth, particularly in regions with limited healthcare resources.
Segmentation: Global Cushing's Disease Market
The global cushing's disease market is segmented on the basis of treatment type, diagnosis, route of administration, end-users, and distribution channel.
- On the basis of treatment type, the global cushing's disease market is segmented into surgery, radiation therapy, drugs, and others.
- On the basis of diagnosis, the global cushing's disease market is segmented into petrosal sinus sampling, saliva test, urine and blood tests, and imaging tests.
- On the basis of route of administration, the global cushing's disease market is segmented into oral, parenteral, and others.
- On the basis of end-users, the global cushing's disease market is segmented into hospitals, specialty clinics, homecare, and others.
- On the basis of distribution channel, the global cushing's disease market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.
Regional Insights: North America dominates the Global Cushing's Disease Market
North America dominates the cushing's disease market due to a surge in research initiatives and the increasing prevalence of obesity, a significant risk factor for the condition. Moreover, substantial healthcare investments and supportive government policies facilitate growth in the region. These factors collectively contribute to North America's dominant position in advancing treatments and raising awareness for cushing's disease.
Asia-Pacific is expected to dominate the cushing's disease market in the forecast period, driven by the rising disposable income levels. This enables improved access to healthcare and specialized treatments. Additionally, ongoing developments in healthcare infrastructure and increased disease awareness are expected to boost market growth. These factors collectively contribute to expanding the cushing's disease market in the Asia-Pacific region.
To know more about the study visit, https://www.databridgemarketresearch.com/reports/global-cushings-disease-market
Recent Developments
- In March 2020, the U.S. Food and Drug Administration (FDA) approved Isturisa (osilodrostat) oral tablets for treating Cushing's disease in adults unable to undergo pituitary gland surgery or who have not achieved remission after surgery. Isturisa represents the first FDA-approved medication to address cortisol overproduction by inhibiting the enzyme 11-beta-hydroxylase, effectively halting cortisol production.
The Prominent Key Players Operating in the Global Cushing's Disease Market Include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Zydus Cadila (India)
- AstraZeneca (U.K.)
- Johnson & Johnson (U.S.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Bristol-Myers Squibb Company (U.S.)
- Eli Lilly and Company (U.S.)
- Strides Pharma Science Limited (India)
- Cipla Inc. (U.S.)
- LEO Pharma A/S (Denmark)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
Above are the key players covered in the report, to know about more and exhaustive list of global cushing's disease market companies contact, https://www.databridgemarketresearch.com/contact
Research Methodology: Global Cushing's Disease Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
